raltegravir potassium

DRUG4 trials

Sponsors

Merck Sharp & Dohme LLC, French National Agency for Research on AIDS and Viral Hepatitis, ANRS, Emerging Infectious Diseases

Conditions

Evidence of Liver TransplantationHIV InfectionHIV InfectionsLiver Failure

Phase 1

Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients

CompletedNCT01022476

ANRS, Emerging Infectious DiseasesEvidence of Liver Transplantation, HIV Infection, Liver Failure

Start: 2010-05-31End: 2013-05-31Updated: 2013-07-18

Phase 2

Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses

CompletedNCT00460382

French National Agency for Research on AIDS and Viral HepatitisHIV Infections

Start: 2007-05-31End: 2009-09-30Updated: 2010-09-17

Phase 3

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)

CompletedNCT00293267

Merck Sharp & Dohme LLCHIV Infections

Start: 2006-02-28End: 2011-05-31Updated: 2015-09-07

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)

CompletedNCT00293254

Merck Sharp & Dohme LLCHIV Infections

Start: 2006-02-28End: 2011-05-31Updated: 2017-03-21

Related Papers

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

UNC Libraries2020-01-082 citations

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

UNC Libraries2020-01-082 citations

Raltegravir with optimized background therapy for resistant HIV-1 infection.

2008-07-01501 citations

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

2008-07-01388 citations